Category News

Takeda and The New York Academy of Sciences announced the winners of the 2024 Innovators in Science Award for their excellence in and commitment to innovative science that has significantly advanced the field of research in cancer immunology.

Takeda and The New York Academy of Sciences today announced the winners of the 2024 Innovators in Science Award for their excellence in, and commitment to, innovative science that has significantly advanced the field of research in cancer immunology. Each…

Merck Healthcare announced a license agreement with Abbisko Therapeutics for pimicotinib, which is currently being evaluated in a Phase 3 study for the treatment of tenosynovial giant cell tumor.

Merck Healthcare today announced a license agreement with Abbisko Therapeutics Co. Ltd, Shanghai, China, for pimicotinib (ABSK021), which is currently being evaluated in a Phase III study for the treatment of tenosynovial giant cell tumor (TGCT). TGCT is a benign…

Positive results from the Phase 3 INAVO120 study of the investigational therapy, inavolisib, in combination with palbociclib and fulvestrant as a potential first-line treatment option for people with PIK3CA-mutated, HR-positive, HER2-negative, endocrine-resistant, locally advanced or metastatic breast cancer.

Genentech, a member of the Roche Group, announced positive results from the Phase III INAVO120 study of the investigational therapy, inavolisib, in combination with palbociclib (Ibrance®) and fulvestrant as a potential first-line treatment option for people with PIK3CA-mutated, hormone receptor…

Vincent Minvielle, Group CSR Director at Servier, talks about the Group’s new trajectory in terms of reducing its greenhouse gas emissions, and in particular about the actions to optimize energy consumption.

Vincent, what is Servier’s approach to the topic of decarbonization, and more specifically the “energy transition”?  The Group’s 2030 vision is very clear: we want to have a significant social impact for patients and for a sustainable world.   As a…

BD launched a new, advanced ultrasound system designed to help improve clinician efficiency when placing peripherally inserted central catheters, central venous catheters, IV lines and other vascular access devices.

BD (Becton, Dickinson and Company), a leading global medical technology company, launched a new, advanced ultrasound system designed to help improve clinician efficiency when placing peripherally inserted central catheters (PICCs), central venous catheters, IV lines and other vascular access devices.…